Plus Therapeutics Inc.

Contributing Author

Recent Articles by Plus Therapeutics Inc.

Nov-24	Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ in Leptomeningeal Metastases PSTV GlobeNewswire
Nov-20	Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer PSTV GlobeNewswire
Nov-17	Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement PSTV GlobeNewswire
Nov-06	Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0 PSTV GlobeNewswire
Oct-30	Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights PSTV GlobeNewswire
Oct-21	Plus Therapeutics Updates on CNSide Diagnostic Platform Launch PSTV GlobeNewswire
Sep-25	Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer PSTV GlobeNewswire
Sep-22	Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT PSTV GlobeNewswire
Sep-18	Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide Diagnostics Clinical Laboratory PSTV GlobeNewswire
Sep-02	Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference PSTV GlobeNewswire
Aug-26	Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria PSTV GlobeNewswire
Aug-18	Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ in Leptomeningeal Metastases PSTV GlobeNewswire
Aug-15	Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements PSTV GlobeNewswire
Aug-14	Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights PSTV GlobeNewswire
Aug-14	Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference PSTV GlobeNewswire
Jul-31	Plus Therapeutics Provides US Launch Update for its CNSide Diagnostic PSTV GlobeNewswire
Jul-23	Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT PSTV GlobeNewswire
Jul-15	Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ in Patients with Leptomeningeal Metastases PSTV GlobeNewswire
Jul-10	Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference PSTV GlobeNewswire
Jul-08	Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases PSTV GlobeNewswire
Jun-30	Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases PSTV GlobeNewswire
Jun-26	Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary PSTV GlobeNewswire
Jun-25	Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET PSTV GlobeNewswire
Jun-25	Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer PSTV GlobeNewswire
Jun-24	Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing PSTV GlobeNewswire
May-30	Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights PSTV GlobeNewswire
May-23	Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q PSTV GlobeNewswire
May-14	Plus Therapeutics' REYOBIQ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) PSTV GlobeNewswire
May-08	Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference PSTV GlobeNewswire

Plus Therapeutics Inc.

Recent Articles by Plus Therapeutics Inc.

Upgrade your FINVIZ experience